PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control number

<u> </u>			995, no per	sons are required	to respo	and to a collection	on of into unless i	t contains a valid OMB control number.			
& TSS Stitute for form 1449A/PTO				C mplete if Known							
	7 CO STOCK OF THE			10/614,59	10/614,599						
INFORMATION DISCLOSURE STATEMENT				July 7, 2003							
BTAP	BY APPLICANT				First Named Inventor			David P. Andrew			
	(use as	many sheets as necessa	ary)	Group Art L	Jnit		1647				
Sheet	1	of 3	_	Attorney Do	ocket No	ımber	09800080	-0104			
			U.S. P	ATENT DOC	UMEN	ITS					
Examiner	Cite No.1	Document Number Public		cation Date	ation Date Name of Pate		Pages, Columns, Lines, W Relevant Passages or Rel				
Initials		Number-Kind Code ^{2 (# known)}	MM	DD-YYYY Applicant of Cited		Document Figures Appear					
Y NO	1	5,871,697	02/	16/1999 Rothberg et al.							
		F	OREIGN	PATENT D	OCUM	ENTS					
Examiner	Cite No.1	Foreign Patent Number	r	Publication Da	e Name of Pat		tentee or	Pages, Columns, Lines, Where Relevant Passages or			
Initials*		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Applicant of Cite	ed Document	Relevant Figures Appear			
M	2	WO 97/34013		09/18/199	- 1	MAN Genome Sciences, Inc.					
	3	WO 99/47669		09/23/199	9 S	Schmitt et al.					
	4	WO 01/00828		01/04/200	1 C	1 Corixa Corp.					
Examin Signatu		PHUQ	B	X		Dat Cor	e nsidered	624106			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unque citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

type a plus sign (+) inside this box ™ +

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

Complete if Known Substitute for form 1449B/PTO 10/614.599 **Application Number** INFORMATION DISCLOSURE July 7, 2003 Filing Date STATEMENT BY APPLICANT David P. Andrew First Named Inventor 164 Group Art Unit Regina M. Deberry (use as many sheets as necessary) **Examiner Name** Sheet of |3|09800080-0104 Attorney Docket No. OTHER ITEMS - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the T² Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials* publisher, city and/or country where published. ADAMS, M.D. et al., "EST 186826 HCC Cell Line (Metastasis to Liver in Mouse) II Homo Sapiens CDNA 5' End mRNA Sequence", Accession Number: AA315020, 1997, AND Adams M.D. et al., "Initial Assessment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA", Nature, vol. 377, (1995), pp 3-174. CAMBY, I., F. Lefranc, et al., "Differential expression of \$100 Calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours", Neuropathology and Applied Neurobiology, 26 (2000), pp 76-DALE, I., M. K. Fagerhol, et al., "Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen", Euro J Biochem 134 (1983), pp 1-6. DE FERRARI, G. V. and N. C. Inestrosa, "Wnt signaling function in Alzheimer's disease", Brain Research Reviews 33 (2000), p 1-12. 9 DJUKANOVIC, D., U. Hofmann, et al., "Comparison of \$100 protein and MIA protein as serum marker for malignant melanoma", Anticancer Research, 20 (2000), pp 2203-2208. DONATO, R., "Functional roles of \$100 proteins, calcium-binding proteins of the 10 EP-hand type", Biochimica et Biophysica Acta 1450 (1999), pp 191-231. HUANG, X., A contig assembly program based on sensitive detection of fragment 11 overlaps" Genomics 14 (1992), pp 18-25. 12 KERLAVAGE, A.R., Direct Submission. GenBank Accession Number AA315020, 1997, pp 1-2. KLIGMAN, D. and D. C. Hilt, "The S100 protein family", Trends Biochemistry 13 Science 13 (1988), pp 437-443. 14 KUHL, M., L. C. Sheldahl, et al., "The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape", Trends Genet 16 (2000), pp 279-283. 15 MARRA, M. et al., "The WashU-HMMI Mouse EST Project", Accession Number: W20659, (1996), Nucleotides, pp. 1-1074. 16 MARRA, M. et al., "The WashU-HHMI Mouse EST Project", Accession Number: W34209, (1997), Nucleotides, pp 166-377.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RM DeBer

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

OEM	. Co - C-	1440D/DTO	Complete if Known						
Substitute for form 1449B/PTO				10/614,599					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	July 7, 2003					
			Filing Date	David P. Andrew					
O A			First Named Inventor	David F. Alidiew					
			Group Art Unit	107					
		use as many sheets as necessary)	Examiner Name	Regina M. Deberry					
Sheet		3 of 3	Attorney Docket No.	09800080-0104					
		OTHER ITEMS - NON PATE	NT LITERATURE DOCU	MENTS					
Examiner Cite item (book, magazine, journal, serial,		item (book, magazine, journal, serial, syn	AL LETTERS), title of the article (when appropriate), title of the ymposium, catalog, etc.), date, page(s), volume-issue number(s), city and/or country where published.						
/RV)	17	MARRA, M. et al., "The WashU-HHMI Mouse EST Project", Accession Number: AA638675, (1997), Nucleotides, pp. 175-386.							
	18	MARRA, M. et al., "The WashU-HHMI Mouse EST Project", Accession Number: 726094, (1998), Nucleotides, pp. 1-483.							
	19	NACKEN, W., C. Sopalla, et al., '	Biochemical characteri						
\		S100A9 (MRP14) protein suggest							
		(2000), pp 560-565.	e its low degree of sequence homology", Eur J Biochem 267						
	20	PATAPOUTIAN, A. and L. F. Reichardt, "Roles of Wnt proteins in neural							
		development and maintenance" Curr Opin Neurobiol 10 (2000), pp 392-399.							
	21	PEIFER, M. and P. Polakis, "Wnt signaling in oncogenesis and embryogenesisa look outside the nucleus", Science 287 (2000), pp 1606-1609.							
	22	PIETAS, et al., "Human cDNA of a new member of the s100 protein family which							
		is downregulated in lung carcinoma cells" Direct Submission. GenBank Accession Number: AY007220, 2000, pp 1-2.							
	23	SASTRY, M., R. R. Ketchem, et al., "The three-dimensional structure of Ca(2+)-							
		bound calcyclin: implications for Ca(2+)-signal transduction by S100 proteins", Structure 6 (1998), pp 223-231.							
	24	SHENG, J. G., R. E. Mrak, et al.,	•	• •					
		S100beta precedes the appearance mice", J Neurochem 74 (2000), pp		d plaques in APPV717F					
	25	SHIMKETS, R. A., D. G. Lowe, e		analysis by transcript					
\		profiling coupled to a gene database query", Nature Biotechnology 17 (1999), pp 798-803.							
	26	SMALLEY, M. J. and T. C. Dale, cancer" Cancer Metastasis Rev 18		<u> </u>					
$M_{\bullet} \cap$	27	XU, K. and C. L. Ceczy, "IFN-gar	nma and TNF regulate	macrophage expression of					
		the chemotacitic S100 protein S10	0A8", The Journal of I	mmunology (2000), pp					
Examine	<u>, </u>	4916 ₇ 4923. /	Date	1/7 /7	Ц				
Signatur		-rurum mal	Consid	lered AAAH	1				

INFORMATION DISCLOSURE STATEMENT				Docket Number: 11669.191USC1		Application Number: 10/614,599			
IN AN APPLICATION				Applicant: ANDREW ET AL.					
لا 1 3 2005 كا الا ا	(Use several sheets if necessary)			Filing Date: 07/07/20		Group Art Unit: 1032 647			
UN 1 3 2005 5				•					
	**	ı	J.S. PATENT DOCU	MENTS					
EXAMINER INITIAL	DOCUMENT NO. DATE		NAME	CLASS	SUBCLASS		FILING DATE IF APPROPRIATE		
<u> </u>									
		 							
:									
*****	_	FOR	EIGN PATENT DO	CUMENTS					
- .	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	ASS	TRANSLATION		
10							YES	NO	
M()	WO 00/55173	09/21/2000	PCT						
	2								
w w		1							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

23552
PATENT TRADEMARK OFFICE

EXAMINER DATE CONSIDERED 0 24 06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; drawline through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.